Three-year safety and efficacy of treating all-comers with newer-generation Resolute Integrity or PROMUS Element stents in the randomised Dutch PEERS (TWENTE II) trial

Liefke C. van der Heijden, Marlies M. Kok, Marije M. Löwik, Peter W. Danse, Gillian A.J. Jessurun, Raymond W.M. Hautvast, Gert K. van Houwelingen, Martin G. Stoel, Marc Hartmann, Gerard C.M. Linssen, Carine J.M. Doggen, Clemens Von Birgelen*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

11 Citations (Scopus)
58 Downloads (Pure)

Abstract

Aims: The aim of this report was to assess the three-year safety and efficacy of implanting newer-generation Resolute Integrity zotarolimus-eluting stents (ZES) versus PROMUS Element everolimus-eluting stents (EES) in all-comers.

Methods and results: In the randomised, multicentre, investigator-initiated Dutch PEERS trial, a total of 1,811 all-comers were 1:1 randomly assigned to treatment with ZES versus EES. A total of 1,293 patients (72%) were treated for complex lesions and 455 patients (25%) were treated for multiple lesions. The primary endpoint target vessel failure (TVF) is a composite of cardiac death, target vessel-related myocardial infarction or target vessel revascularisation. Adverse clinical events were independently adjudicated. Three-year follow-up data were obtained in 1,807 patients (99.8%, four withdrawals). Both the ZES and EES groups showed favourable outcomes with a similar incidence of TVF (10.7% vs. 10.3%; pLog-rank =0.77) and the individual components thereof: cardiac death (3.2% vs. 3.1%; pLog-rank=0.87), target vessel-related myocardial infarction (2.8% vs. 2.2%; pLog-rank =0.44) and target vessel revascularisation (6.0% vs. 6.2%; pLog-rank =0.87). In addition, the incidence of definite or probable stent thrombosis was similar for patients treated with ZES versus EES (1.4% vs. 1.1%; pLog-rank =0.66).

Conclusions: The safety and efficacy of treating all-comers with newer-generation Resolute Integrity and PROMUS Element stents was found to be extended up to three years.

Original languageEnglish
Pages (from-to)2128-2131
Number of pages4
JournalEuroIntervention
Volume12
Issue number17
DOIs
Publication statusPublished - 1 Apr 2017

Fingerprint

Stents
Safety
Myocardial Infarction
Incidence
Thrombosis
Research Personnel
zotarolimus
Everolimus

Keywords

  • Newer-generation drug-eluting stent
  • Percutaneous coronary intervention
  • PROMUS Element everolimus-eluting stent
  • Resolute integrity zotarolimus-eluting stent

Cite this

van der Heijden, Liefke C. ; Kok, Marlies M. ; Löwik, Marije M. ; Danse, Peter W. ; Jessurun, Gillian A.J. ; Hautvast, Raymond W.M. ; van Houwelingen, Gert K. ; Stoel, Martin G. ; Hartmann, Marc ; Linssen, Gerard C.M. ; Doggen, Carine J.M. ; Von Birgelen, Clemens. / Three-year safety and efficacy of treating all-comers with newer-generation Resolute Integrity or PROMUS Element stents in the randomised Dutch PEERS (TWENTE II) trial. In: EuroIntervention. 2017 ; Vol. 12, No. 17. pp. 2128-2131.
@article{bbfc7fcdc24b474b96c5b319e13c31e8,
title = "Three-year safety and efficacy of treating all-comers with newer-generation Resolute Integrity or PROMUS Element stents in the randomised Dutch PEERS (TWENTE II) trial",
abstract = "Aims: The aim of this report was to assess the three-year safety and efficacy of implanting newer-generation Resolute Integrity zotarolimus-eluting stents (ZES) versus PROMUS Element everolimus-eluting stents (EES) in all-comers. Methods and results: In the randomised, multicentre, investigator-initiated Dutch PEERS trial, a total of 1,811 all-comers were 1:1 randomly assigned to treatment with ZES versus EES. A total of 1,293 patients (72{\%}) were treated for complex lesions and 455 patients (25{\%}) were treated for multiple lesions. The primary endpoint target vessel failure (TVF) is a composite of cardiac death, target vessel-related myocardial infarction or target vessel revascularisation. Adverse clinical events were independently adjudicated. Three-year follow-up data were obtained in 1,807 patients (99.8{\%}, four withdrawals). Both the ZES and EES groups showed favourable outcomes with a similar incidence of TVF (10.7{\%} vs. 10.3{\%}; pLog-rank =0.77) and the individual components thereof: cardiac death (3.2{\%} vs. 3.1{\%}; pLog-rank=0.87), target vessel-related myocardial infarction (2.8{\%} vs. 2.2{\%}; pLog-rank =0.44) and target vessel revascularisation (6.0{\%} vs. 6.2{\%}; pLog-rank =0.87). In addition, the incidence of definite or probable stent thrombosis was similar for patients treated with ZES versus EES (1.4{\%} vs. 1.1{\%}; pLog-rank =0.66). Conclusions: The safety and efficacy of treating all-comers with newer-generation Resolute Integrity and PROMUS Element stents was found to be extended up to three years.",
keywords = "Newer-generation drug-eluting stent, Percutaneous coronary intervention, PROMUS Element everolimus-eluting stent, Resolute integrity zotarolimus-eluting stent",
author = "{van der Heijden}, {Liefke C.} and Kok, {Marlies M.} and L{\"o}wik, {Marije M.} and Danse, {Peter W.} and Jessurun, {Gillian A.J.} and Hautvast, {Raymond W.M.} and {van Houwelingen}, {Gert K.} and Stoel, {Martin G.} and Marc Hartmann and Linssen, {Gerard C.M.} and Doggen, {Carine J.M.} and {Von Birgelen}, Clemens",
year = "2017",
month = "4",
day = "1",
doi = "10.4244/EIJ-D-16-00571",
language = "English",
volume = "12",
pages = "2128--2131",
journal = "EuroIntervention",
issn = "1774-024X",
publisher = "EuroPCR",
number = "17",

}

van der Heijden, LC, Kok, MM, Löwik, MM, Danse, PW, Jessurun, GAJ, Hautvast, RWM, van Houwelingen, GK, Stoel, MG, Hartmann, M, Linssen, GCM, Doggen, CJM & Von Birgelen, C 2017, 'Three-year safety and efficacy of treating all-comers with newer-generation Resolute Integrity or PROMUS Element stents in the randomised Dutch PEERS (TWENTE II) trial', EuroIntervention, vol. 12, no. 17, pp. 2128-2131. https://doi.org/10.4244/EIJ-D-16-00571

Three-year safety and efficacy of treating all-comers with newer-generation Resolute Integrity or PROMUS Element stents in the randomised Dutch PEERS (TWENTE II) trial. / van der Heijden, Liefke C.; Kok, Marlies M.; Löwik, Marije M.; Danse, Peter W.; Jessurun, Gillian A.J.; Hautvast, Raymond W.M.; van Houwelingen, Gert K.; Stoel, Martin G.; Hartmann, Marc; Linssen, Gerard C.M.; Doggen, Carine J.M.; Von Birgelen, Clemens.

In: EuroIntervention, Vol. 12, No. 17, 01.04.2017, p. 2128-2131.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Three-year safety and efficacy of treating all-comers with newer-generation Resolute Integrity or PROMUS Element stents in the randomised Dutch PEERS (TWENTE II) trial

AU - van der Heijden, Liefke C.

AU - Kok, Marlies M.

AU - Löwik, Marije M.

AU - Danse, Peter W.

AU - Jessurun, Gillian A.J.

AU - Hautvast, Raymond W.M.

AU - van Houwelingen, Gert K.

AU - Stoel, Martin G.

AU - Hartmann, Marc

AU - Linssen, Gerard C.M.

AU - Doggen, Carine J.M.

AU - Von Birgelen, Clemens

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Aims: The aim of this report was to assess the three-year safety and efficacy of implanting newer-generation Resolute Integrity zotarolimus-eluting stents (ZES) versus PROMUS Element everolimus-eluting stents (EES) in all-comers. Methods and results: In the randomised, multicentre, investigator-initiated Dutch PEERS trial, a total of 1,811 all-comers were 1:1 randomly assigned to treatment with ZES versus EES. A total of 1,293 patients (72%) were treated for complex lesions and 455 patients (25%) were treated for multiple lesions. The primary endpoint target vessel failure (TVF) is a composite of cardiac death, target vessel-related myocardial infarction or target vessel revascularisation. Adverse clinical events were independently adjudicated. Three-year follow-up data were obtained in 1,807 patients (99.8%, four withdrawals). Both the ZES and EES groups showed favourable outcomes with a similar incidence of TVF (10.7% vs. 10.3%; pLog-rank =0.77) and the individual components thereof: cardiac death (3.2% vs. 3.1%; pLog-rank=0.87), target vessel-related myocardial infarction (2.8% vs. 2.2%; pLog-rank =0.44) and target vessel revascularisation (6.0% vs. 6.2%; pLog-rank =0.87). In addition, the incidence of definite or probable stent thrombosis was similar for patients treated with ZES versus EES (1.4% vs. 1.1%; pLog-rank =0.66). Conclusions: The safety and efficacy of treating all-comers with newer-generation Resolute Integrity and PROMUS Element stents was found to be extended up to three years.

AB - Aims: The aim of this report was to assess the three-year safety and efficacy of implanting newer-generation Resolute Integrity zotarolimus-eluting stents (ZES) versus PROMUS Element everolimus-eluting stents (EES) in all-comers. Methods and results: In the randomised, multicentre, investigator-initiated Dutch PEERS trial, a total of 1,811 all-comers were 1:1 randomly assigned to treatment with ZES versus EES. A total of 1,293 patients (72%) were treated for complex lesions and 455 patients (25%) were treated for multiple lesions. The primary endpoint target vessel failure (TVF) is a composite of cardiac death, target vessel-related myocardial infarction or target vessel revascularisation. Adverse clinical events were independently adjudicated. Three-year follow-up data were obtained in 1,807 patients (99.8%, four withdrawals). Both the ZES and EES groups showed favourable outcomes with a similar incidence of TVF (10.7% vs. 10.3%; pLog-rank =0.77) and the individual components thereof: cardiac death (3.2% vs. 3.1%; pLog-rank=0.87), target vessel-related myocardial infarction (2.8% vs. 2.2%; pLog-rank =0.44) and target vessel revascularisation (6.0% vs. 6.2%; pLog-rank =0.87). In addition, the incidence of definite or probable stent thrombosis was similar for patients treated with ZES versus EES (1.4% vs. 1.1%; pLog-rank =0.66). Conclusions: The safety and efficacy of treating all-comers with newer-generation Resolute Integrity and PROMUS Element stents was found to be extended up to three years.

KW - Newer-generation drug-eluting stent

KW - Percutaneous coronary intervention

KW - PROMUS Element everolimus-eluting stent

KW - Resolute integrity zotarolimus-eluting stent

UR - http://www.scopus.com/inward/record.url?scp=85021168271&partnerID=8YFLogxK

U2 - 10.4244/EIJ-D-16-00571

DO - 10.4244/EIJ-D-16-00571

M3 - Article

AN - SCOPUS:85021168271

VL - 12

SP - 2128

EP - 2131

JO - EuroIntervention

JF - EuroIntervention

SN - 1774-024X

IS - 17

ER -